CURRICULUM VITAE
Name:
Nathalie Scholler (née Buonavista), M.D., Ph.D.
Present Position:
Tenure-track Assistant Professor, Department of Obstetrics and Gynecology.
Office:
University of Pennsylvania School of Medicine.
Center for Research on Reproduction and Women's Health
Biomedical Research Building II/III, Room 1309
421 Curie Blvd., Philadelphia, PA, 19104-6160
Phone: (215) 898 0164 – Fax: (215) 573 5129 - naths@mail.med.upenn.edu
http://www.med.upenn.edu/crrwh/faculty/Scholler/Scholler.html
http://www.med.upenn.edu/schollerlab/
Place of Birth:
Marseille, France
Education:
1995
1990
1988
PhD, Immunology
University of Science of Aix-Marseille II, France
Diplôme d’études approfondies (equiv. MS) University of Science of Aix-Marseille II, France.
Immunology
MD, General Medicine
School of Medicine, Marseille, France.
Training:
1995-1997
Post-Doctoral Fellowship
1991-1995
Post-Graduate Fellowship
1986-1988
Internship in General Medicine
Autoimmunity Department, Bristol Myers Squibb
Pharmaceutical Institute, Seattle, WA
Centre d’Immunologie de Marseille-Luminy,
University of Aix-Marseille II, France.
University of Aix-Marseille Affiliated Hospitals,
Marseille, France.
Additional Training:
1993
Human genome analysis: from YAC to gene The 11th Welcome Summer School. United
Medical and Dental Schools of Guy’s and St
Thomas’s Hospitals, London, UK
2004
Engineering of Recombinant Antibodies
Cambridge Healthtech Institute, Needham, MA
Faculty Appointments and Professional Positions:
Nov. 2007-present
Tenure-track Assistant Professor
2003-2007
2001-2003
1997-2001
1990-1995
1989-1990
1988-1989
Department of Obstetrics and Gynecology,
University of Pennsylvania, Philadelphia, PA
Senior Staff Scientist & Laboratory Director Translational and Outcomes Research laboratory,
Molecular Diagnostics Program, Fred Hutchinson
Cancer Research Center, Seattle, WA.
Senior Research Scientist
Department of Biochemistry, Seattle Genetics, Inc.
Bothell, WA.
Staff Research Scientist
Department of Tumor Immunology, Pacific
Northwest Research Institute, Seattle, WA.
Sports Medicine Physician
French National Federation of Judo, Marseille, Fr.
Physician Scientist
French National Institute of Health and Medical
Research (INSERM), France and Brazil.
Resident in Internal Medicine
St Joseph Hospital, Marseille, France.
Page 1
Academic and Institutional committees
2010-present
Penn Institute for Immunology (Penn IFI), UPenn
Member
2010-present
Bioengineering Graduate Studies, Bioengineering Graduate Group, UPenn
Member
2009-present
Biomedical Graduate Studies, Immunology Graduate Group, UPenn
Member
2008-present
FOCUS Advisory Committee, UPenn
Member
2008-present
Immunobiology program, Tumor Immunology Interest Group
Full Research Member
Abramson Cancer Center, UPenn
2007-present
Penn Ovarian Cancer Research Center (Penn OCRC), UPenn
Member
Memberships:
2010-present
2010-present
2008-present
2008-present
2001-present
2001-present
2001-present
New York Academy of Sciences (NYAS)
American Association for Cancer Research (AACR)
Consortium for Functional Glycomics (CFG)
Institute for Translational Medicine and Therapeutics (ITMAT)
American Association of Immunologists (AAI)
American Association for the Advancement of Science (AAAS)
American Society of Gene and Cell Therapy (ASGCT)
Scholarships, Fellowships and Awards:
2011
Junior Faculty Travel Award
2003-2004
Career Development Award
2001-2003
1995
1991-1994
1990
1980-1986
Marsha Rivkin Center Scholar Award
Private fellowship
National scholarship
Private fellowship
Regional scholarship
Organizing roles
2011 Host
2010
Moderator
2010
2009
2008
Block Chair
Block Chair
Block Chair
American Association of Immunologists (AAI 2011)
San Francisco, CA.
Marsha Rivkin Center for Ovarian Cancer Research
(MRCOCR), Seattle, WA.
MRCOCR, Seattle, WA
La Fondation pour la Recherche Médicale, France.
French Ministry of Research & Technology, France.
La Fondation pour la Recherche Médicale, France.
Province des Bouches-du-Rhône, France.
Break-out discussion at the 13th Annual Phage and Yeast Display of Antibodies & Proteins
conference, Protein Engineering Summit (PEGS) - May 9-10 - Boston, MA.
Center for Research on Reproduction and Women’s Health Annual Research Retreat and the
Cuozzo lecture- May 19- University of Pennsylvania, PA.
97th AAI Annual meeting, Tumor Immune Response session - May 7-10 - Baltimore, MD
96th AAI Annual meeting, Tumor Immune Escape - May 8-12 - Seattle, WA
2nd International Conference on Ovarian Cancer: State of the Art and Future Directions - June 26
- July 1- Rhodes, Greece
Scientific Review, Consulting and Advisory roles:
2011
Scientific reviewer for DOD Study section: Ovarian Cancer Research Program, DetectionDiagnosis and Clinical and Experimental Therapeutic, DD-CET
2011
Scientific expert for Wolf, Greenfield & Sacks, P.C., Boston, MA.
2011
Scientific reviewer for Kentucky Science & Engineering Foundation.
2010
Consultant for Reckner Healthcare.
2010
Advisory Board Member at the Editorial Board of Recent Patents on Biomarkers.
Since 2010
Advisory Board member for Cancer Targets and Therapeutics Annual Conferences.
2010
Scientific reviewer for the Health Research Council (HRC), New Zealand.
2010
Scientific reviewer for DOD Study section: Ovarian Cancer Clinical and Experimental
Therapeutics.
2009-2011
Advisory Board tenured Member in the Editorial board of Journal of Proteome Research.
2009
Scientific reviewer for NIH Challenge grants in Health and Science Research (RC1).
2009
Scientific reviewer for The Health Research Board, Ireland.
2008
Scientific reviewer for Maryland Industrial Partnerships (MIPS).
2008
Scientific expert, Ernst & Young, Life and Health Science Advisory, Paris, France
2008
Scientific reviewer for DOD Study section: Ovarian Cancer Research Program.
Page 2
2008
Consultant for Ernst & Young Life and Health Science Advisory, Paris, France.
Editorial Positions
2011-present
2011-present
2011-present
2011-present
2011-present
2011-present
2010-present
2010-present
2010-present
2009-present
2009-present
2009-present
2009-present
2009-present
2006-present
2008-present
2008-present
2008-present
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Associate Editorial Board member
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Author-in-Chief
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Peer-Reviewer
Presentations
2011 Invited speaker
2011
2011
2011
2011
2011
2011
2010
2010
2010
2010
Disease markers.
OMICS: A Journal of Integrative Biology
Nature Communications.
Biomarkers in Medicine
Molecular Pharmaceutics.
Journal of Controlled Release.
Cancer Immunology Immunotherapy.
Journal of Translational Research
Journal of Proteomics
Gynecologic Oncology
PlosONE
Clinical Science
Cancer Epidemiology
Encyclopedia of Cancer, 2nd edition
Cancer Letters
Cancer Biology & Therapy
Gynecologic and Obstetric Investigation
Molecular and Cellular Proteomics
“Novel mechanisms of polarization of tumor-infiltrating macrophages”. Complex
Carbohydrate Research Center, University of Athens. December 5, Athens, GA.
Invited speaker
“Role of tumor-released glycoproteins during macrophage polarization”. Consortium for
Functional Glycomics (CFG) breakout Session. November 9, Seattle, WA.
Poster presentation “Development of T-bodies expressing CIR directed against Endosialin/TEM1 for immunegene therapy against breast cancer”. Nathalie Scholler, Stephen P. Santoro, Shree Joshi,
Aizhi Zhao, and George Coukos, Era of Hope 2011, August 2-5, Orlando, FL.
Invited speaker
“Paired yeast-display/secretory vectors for rapid isolation of site-specific biotinylated
affinity reagents”, 13th Annual Phage and Yeast Display of Antibodies & Proteins
conference, Protein Engineering Summit (PEGS) - May 9-10 - Boston, MA.
Oral presentation
“Tumor released mesothelin contributes to the polarization of tumor-infiltrating
macrophages”, 14th Annual Meeting of the Translational Research Cancer Centers
Consortium conference, Seven Springs Mountain Resort - Feb 24-26 - Seven Springs, PA
Invited speaker
“GPI anchors: much more than an alternative strategy for cell surface presentation”
GTCbio’s 3rd Oncology Biomarker Conference, Jan 27-28, San Diego, CA.
Poster presentation “Tumor-infiltrating B-cells express toll-like receptors and exert proangiogenic activity in
ovarian cancer”. S. Nunez-Cruz, W. Quinn, D. Connolly, P. Gimotty, and N. Scholler.
EMBO 2011 meeting. Immunology & Metabolism- Centre d’Immunologie de MarseilleLuminy, January 13-14, Marseille, France.
Invited speaker
“Role of B cells in cancer development”. 23rd Annual Immunology Retreat. November 5-7.
Lancaster, PA
Invited speaker
“Novel mechanism for M2 polarization of tumor-infiltrating macrophages via GPI-anchored
proteins”. Marsha Rivkin Center Ovarian Cancer Research Symposium, session: On the
Horizon: Developing Therapeutics. Oct 28-29, Seattle, WA.
Invited speaker
“Tumor-infiltrating lymphocytes B (TIL-B) angiogenic properties contribute to tumor
growth in presence of complement”. Department of Immunopathology, NIAID/NIH. June 3,
Rockville, MD.
Invited speaker
“Study of the role of tumor-infiltrating B-cells in a transgenic mouse model of ovarian
cancer”. Tumor Immunology Interest Group. May 20, University of Pennsylvania, PA.
Page 3
Presentations (continue)
2010 Poster presentation "Mannose receptor binding triggers M2-macrophage polarization" Denarda Dangaj, Selene
Nunez-Cruz, Aizhi Zhao and Nathalie Scholler. Canary Foundation Early Detection
Symposium, May 25-27, Stanford, CA
2009 Invited speaker
“Alkali-resistant, site-specific biotinylated, high affinity reagent for IgG capture”. Bio-Rad
laboratories, Dec. 9, Hercules, CA.
2009 Invited speaker
“Tumor-infiltrating B lymphocytes in ovarian cancer”. FCCC-UPENN Quarterly Ovarian
Cancer Research meeting. Fox Chase Cancer Research Center, Dec. 3, Philadelphia PA.
2009 Invited speaker
“Study of the role of CA125 and adipocytes in the alternative complement pathway during
ovarian cancer physiopathology” and “Blocking of CA125/Mesothelin-dependent peritoneal
metastasis with antibodies and biobodies”. Fred Hutchinson Cancer Research Center,
Scientific Program Committee Meeting. Nov 16, Seattle WA.
2009 Poster presentation "Blocking tumor/macrophages cross-talk with anti-mannose receptor recombinant antibodies
to trigger tumor rejection" Denarda Dangaj, Aizhi Zhao, Raphael Sandaltzopoulos, George
Coukos and Nathalie Scholler. 2009 NCI Translational Science Meeting (TSM 2), session:
Therapeutic Antibodies and Combination Therapies, November 5-7, Vienna, VA.
2009 Poster presentation “Characterization of Tumor Infiltrating-B cells (TIL-B) in a transgenic mouse model of
serous ovarian cancer.” Nunez-Cruz, S., Guerra, M., Queen, W., Scott P., Connolly, D.,
Cancro, M.P., Gimotty, P., and Scholler, N. Frontiers in Basic Immunology, NIH, October
1-2, Bethesda, MD.
2009 Invited speaker
“Rapid identification of high affinity reagents using a yeast-expressed recombinant antibody
platform”, Dana Farber/Harvard Medical School, June 19, Boston, MA.
2009 Invited speaker
“Systèmes d’expression d’anticorps recombinants dans la levure: Application en
Immunociblage”. INSERM -U 928- TAGC & UMR 928 Université de la Méditerranée, June
10, Marseille-Luminy, France.
2009 Invited speaker
“Scouting glycoproteins in ovarian cancer”. CRRWH annual retreat, University of
Pennsylvania, May 27, Philadelphia, PA.
2009 Invited speaker
“Yeast-expressed recombinant antibody platform for rapid identification of high affinity
reagents”. Institute of System Biology, May 11, Seattle, WA
2009 Invited speaker
“Role of tumor-released GPI-anchor proteins in macrophage polarization”. Centocor,
University of Pennsylvania, March 16, Philadelphia, PA
2009 Invited speaker
“Biobody technology.” Drexel Institute for Biotechnology and Virology Research at
Pennsylvania Biotechnology Center of Bucks County, March 11, Doylestown, PA.
2009 Invited speaker
“Yeast-expressed recombinant antibody (scFv) for discovery of cancer biomarkers”,
GlaxoSmithKline, March 10, King of Prussia, PA
2009 Invited speaker
“Prevention of ovarian cancer peritoneal metastasis by designing blocking strategies of
CA125/mesothelin interaction using natural or recombinant antibodies.” 6th Cancer Drugs
R&D Conference. February 19-20, Philadelphia, PA.
2009 Invited speaker
“The coming of age of ovarian cancer biomarkers.” 2nd Oncology Biomarkers Conference.
Jan. 19-20, Miami, FL.
2008 Invited speaker
“Using yeast for display and secretion of recombinant antibodies”, LifeSensors, Inc.
October 28, Malvern, PA.
2008 Invited speaker
“Selection of high affinity anti-TEM1 scFv by magnetic and flow sortings of a novel yeastdisplay scFv library”, Bracco Research USA Inc, September 25, Princeton, NJ.
2008 Invited speaker
“Yeast-display scFv and biobodies”, Morphotek, Inc., July 14, Exton, PA.
2008 Invited speaker
“Generation of libraries of recombinant llama heavy-chain for diagnostic and discovery of
cancer markers”. Second International Conference on Ovarian Cancer: State of the Art and
Future Directions, June 26 - July 1, Rhodes, Greece
2008 Poster presentation “Generation of recombinant libraries of heavy-chain V regions derived from Llama Glama”.
Scholler N., Gross J.A. and Urban N. Canary Foundation Early Detection Symposium, May
21-22, Stanford, CA.
2007 Oral presentation
“Development and in vitro Validation of anti-Mesothelin Biobodies that prevent
CA125/Mesothelin-dependent Cell Attachment.”. Bergan L, Gross JA, Nevin B, Urban N
and Scholler N. 15th SPORE Investigators’ Workshop Concurrent Poster Discussion
Page 4
2007
2007
2007
2007
2006
2006
2006
2006
2006
2006
2006
2005
2004
2004
2002
2001
2001
Session: New Technologies and Methodologies in Translational Research II, July 7-10,
Baltimore, MA.
Poster presentation “Development and in vitro validation of anti-mesothelin biobodies that prevent
CA125/Mesothelin-dependent cell attachment.” Scholler N, Bergan L, Gross JA, Garvik B,
Nevin B, and Urban N. Federation of Clinical Immunology Societies (FOCIS) annual
meeting, June 7-11, San Diego, CA.
Poster presentation “Generation of a new type of yeast-secreted biotinylated recombinant antibodies directed
against mesothelin and able to prevent CA125/mesothelin-dependent cell attachment.”.
Scholler N, Garvik B, Bergan L, Nevin B, Gross JA, and Urban N. ASGT 10th Annual
Meeting, May 30 - June 3, Seattle, WA.
Invited speaker
“Design of new classes of recombinant antibodies and validation for use in cancer
diagnostics and therapy.” University of Pennsylvania May 16, Philadelphia, PA.
Poster presentation “Validation of in vivo-biotinylated yeast-secreted recombinant antibodies for use in
diagnostic tests.” Scholler N, Lowe K, Bergan L, Kampani A, Gross JA, Garvik B and
Urban N. - BioMarker World Congress 2007, May 15–17, Philadelphia, PA.
“
Invited speaker
Utilisation d'un test d'adhésion cellulaire basé sur l'interaction CA125/mésotheline pour
tester in vitro de nouvelles voies d'approches thérapeutiques pour la prévention de micrométastases péritonéales du cancer de l'ovaire.” Institut de Cancérologie et d'Immunologie de
Marseille IFR 137 (Institute of Cancer and Immunology) INSERM UMR 599, November
15, Marseille, France.
Invited speaker
“Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.”
Laboratoire Technologies Avancées pour le Génome et la Clinique TAGC (Laboratory of
Advanced Technology for Genome and Clinic) ERM 0206, November 14, Marseille –
Luminy, France.
Invited speaker
“Generation of antigen-specific recombinant antibodies in the absence of purified and/or
immunogenic antigens.” Seattle Biomedical Research Institute, November 6, Seattle, WA.
Invited speaker
“Generation of New Tools for Early Detection of Ovarian Cancer.” Complex Carbohydrate
Research Center, University of Athens. September 29, Athens, Georgia.
Oral presentation
“Bead-Based ELISA Assays for Validation of Ovarian Cancer Early Detection Markers.” Scholler N, Crawford M, Sato A, Drescher CW, O’Briant KC, Kiviat N, Anderson GL and
Urban ND. Sixth Biennial Symposium sponsored by the MRCOCR, September 7-8, Seattle,
WA.
Oral presentation
“Development of a CA125-Mesothelin Cell Adhesion Assay as a Screening Tool for
Biologics Discovery.” Scholler N, Garvik B, Hayden-Ledbetter M, Kline T and Urban ND.
Fourteenth SPORE Investigators’ Workshop Concurrent Plenary session, July 16-19,
Baltimore MA.
Poster presentation. “Biobodies: generation and validation.” Scholler, N. and Garvik, B. American Association of
Immunologists, May 12–16, Boston, MA.
Oral Presentation “Sandwich test ELISA with scFv antibodies: an alternative to an all-time favorite”- Scholler
N, Garvik B and Urban N. Symposium of the Era of Hope Department of Defense Breast
Cancer Research, Philadelphia, PA.
Poster presentation “Generating New Tools for CD83 Functional Studies: Identification of an Anti-CD83
Recombinant Antibody that Binds to an HB15-Alternate Epitope” Hamel Y, Greenberg P
and Scholler N. Twelfth International Congress of Immunology, Montreal, Canada.
Oral presentation “Isolation of ovarian carcinoma-specific native proteins for development of new biomarkers.”
Scholler N, Lampe P and Urban N. Eleventh SPORE Investigators Workshop, Baltimore,
MD.
Oral presentation
“CD83 regulates the development of cellular immunity”. Scholler N, Hayden-Ledbetter M,
Dahlin A, Hellström I, Hellström KE and Ledbetter JA. FASEB Immunology, New Orleans,
LA.
Oral presentation
“CD83 is a adhesion receptor that binds monocytes and activated CD8+T cells” Scholler N,
Disis ML, Dahlin A, Pullman J, Hellström KE and Hellström I. Eleventh International
Congress of Immunology, Stockholm, Sweden.
Oral presentation
“HER2 DNA immunization with costimulatory molecules elicits functional anti-HER2
antibodies and CD4+ T cell tumor infiltration.” Scholler N, Ledbetter M., Hellström KE,
Page 5
2001
2001
2000
1998
1994
1992
Hellström I, Ledbetter JA - Eleventh International Congress of Immunology, Stockholm,
Sweden.
Oral presentation
“HER2 DNA immunization with costimulatory molecules elicits functional anti-HER2
Antibodies.”. Scholler N, Disis ML, Dahlin A, Pullman J, Hellström KE and Hellström I Fourth Annual Meeting of the ASGT, Seattle, WA. Abstract published in Molecular
Therapy. 3(5): S69-70.
Poster presentation “HER2 DNA immunization with costimulatory molecules”. Scholler N, Disis ML, Dahlin A,
Pullman J, Hellström KE and Hellström I. Ninth SPORE Investigators Workshop,
Washington, DC.
Oral presentation
“Antibodies to the HER2 protein can be elicited with DNA immunization.” Scholler N, Disis
ML, Pullman J, Hellström KE and Hellström I - Third Biennial Ovarian Cancer Research
Symposium, Seattle, WA.
Oral presentation
“DNA immunization with a combination of Rat Neu antigen, CD86 and 4-1BB ligand results
in the generation of HER-2/neu (HER2) antibodies in Neu transgenic (neuT) mice.” Scholler
N, Shiota FM, Pullman J, Hellström KE, Hellström I and Disis ML. Seventh International
Conference on Gene Therapy of Cancer, Coronado, CA.
Poster presentation “Mapping of CTLA4-CD28 genomic region by yeast artificial chromosomes (YAC).”
Buonavista N, Balzano C, Pontarotti P, Le Paslier D and Goldstein P.- May 11-15,
Workshop Genome mapping and sequencing, Cold Spring Harbor, NY.
Invited speaker
“Interest and advantage of YAC technology for genome mapping”- September 15,
Workshop Pulse Field Electrophoresis, Pharmacia, France.
Abstracts
2011 “Blocking B7-H4- mediated T-cell inhibition to alter the tumor microenvironment”, Denarda Dangaj, Shree Joshi,
Aizhi Zhao, Raphael Sandaltzopoulos and Nathalie Scholler. Poster presentation, 26th Annual Meeting of the
Society for Immunotherapy of Cancer (SITC), November 4-6, 2011, Bethesda, MD.
2011 “Characterization of a TEM1 tumor-targeting antibody”. George Coukos, Aizhi Zhao, Chunsheng Li, Daniel
Ricklin, Tamara Seedial, and Nathalie Scholler, Era of Hope 2011, Orlando, FL.
2011 “Developing magnetic nanoparticles for targeted nucleic acid delivery and detection” Poster presentation.
Prantner A.M., Chen J., Murray C.B., and Scholler N. ASGCT 2011, May7 17-21, Seattle, WA.
2011 “B cells infiltrating ovarian cancer exhibit a regulatory-like phenotype.” Selene Nunez-Cruz, William J. Quinn III,
Denise C. Connolly and Nathalie Scholler. Oral presentation, The Journal of Immunology, 2011 supplement, AAI
2011, May 13-17, San Francisco, CA. Travel Award, Selene Nunez-Cruz.
2011 “Mannose receptor regulates macrophage polarization in the tumor microenvironment” Denarda Dangaj, Shree
Joshi, Aizhi Zhao, Raphael Sandaltzopoulos and Nathalie Scholler. Poster presentation, The Journal of
Immunology, 2011 supplement, AAI 2011, May 13-17, San Francisco, CA.
2011 “Role of TLR engagement on TIL-B and clinical implications for ovarian cancer.” Selene Nunez-Cruz, Matthew
Guerra, Denise Connolly, Phyllis Gimotty and Nathalie Scholler. Poster presentation, AACR 2011, April 2-5,
Orlando, FL.
2011 “Developing targeted superparamagnetic iron oxides for combination chemohyperthermia” Prantner A.M., Chen
J., Murray C.B., and Scholler N. Poster presentation, Immunochemotherapy: Correcting Immune Escape in
Cancer, March 10, Philadelphia, PA.
2011 “Modeling the human tumor-microenvironment in CD34 transplanted NSG mice” Marc Walter, Selene NunezCruz, Ananda Mookerjee, Chongyun Fang, Andrea Facciabene, George Coukos, Gwenn Danet-Desnoyers and
Nathalie Scholler. Poster presentation, Immunochemotherapy: Correcting Immune Escape in Cancer, March 10,
Philadelphia, PA.
2011 “Reconstitution of the human ovarian tumor-microenvironment in CD34-transplanted NOD-Scid-IL2Rc null
(NSG) mice.” Marc Walter, Ananda Mookerjee, Selene Nunez-Cruz, Chongyun Fang, Andrea Facciabene, Daniel
J. Powell Jr., George Coukos, Nathalie Scholler, and Gwenn Danet-Desnoyers. Poster presentation, TRC3 2011,
February 24-26, Seven Springs, PA
2011 “Modulation of the tumor microenvironment by targeting the co-inhibitory B7H4 molecule”. Denarda Dangaj,
Shree Joshi, Aizhi Zhao, Daniel J. Powell Jr., Raphael Sandaltzopoulos and Nathalie Scholler. Poster
presentation, TRC3 2011, February 24-26, Seven Springs, PA
2010 “Characterization of scFv78: an anti-TEM1 scFv” Aizhi Zhao, Chunsheng Li, Daniel Ricklin, Tamara Seedial,
George Coukos, Nathalie Scholler. International Society for Biological Therapy of Cancer (iSBTc). Poster
Page 6
2010
2010
2010
2010
2010
2010
2010
2010
2010
2010
2010
2009
2009
2009
2009
presentation, October 2 - 4, Washington, D.C. The Journal of Immunotherapy, in press.
“Targeting of superparamagnetic iron oxide nanoparticles for cancer therapy based on localized hyperthermia”
Andrew M. Prantner, Jun Chen, Christopher B. Murray and Nathalie Scholler. 6th annual Symposium Center for
Translational Medicine, oral and poster presentations, June 4, Jefferson Medical College, Philadelphia, PA
“The binding of mannose receptor by tumor-released GPI-anchor proteins controls tumor-associated macrophage
phenotype”, Denarda Dangaj, Selene Nunez-Cruz, Aizhi Zhao, Raphael Sandaltzopoulos and Nathalie Scholler.
Oral presentation, CRRWH annual retreat, University of Pennsylvania, PA. Presentation winner, D. Dangaj.
“Gold nanorods conjugated to tumor-specific antibody for the targeting of ovarian cancer” Kolin C. Hribar,
Gregory R. Wiedman, Andrew Prantner, Chaitanya Divgi, and Nathalie Scholler. Senior Design project of
undergraduate students in Bioengineering, poster presentation, April 20, University of Pennsylvania, School of
Engineering, PA.
“Ovarian tumor infiltrating lymphocytes B (TIL-B) present pro-angiogenic properties.” Selene Nunez-Cruz,
Matthew Guerra, Denise Connolly, George Coukos, Phyllis Gimotty and Nathalie Scholler - The Journal of
Immunology, 2010, 184, 101.7; AAI 2010, Poster and oral presentations. May 7-10, Baltimore, MD. Trainee
Achievement Award, Selene Nunez-Cruz.
“Comparative screening of human antibody libraries derived from autoimmune vs. cancer patients for affinity
reagents directed against tumor-associated antigens”. Aizhi Zhao, Yi Cheng, George Coukos, Don Siegel, and
Nathalie Scholler. - The Journal of Immunology, 2010, 184, 101.20 AAI 2010, Poster presentation. May 7-10,
Baltimore, MD.
“Tumor-released GPI-anchored proteins bind to mannose receptor and polarize tumor-infiltrating macrophages.”
Denarda Dangaj, Aizhi Zhao, Selene Nunez-Cruz, Raphael Sandaltzopoulos and Nathalie Scholler - AACR 2010
Poster presentation. April 20, Washington, DC.
“Genetic and pharmaceutical approaches for the study of complement factors as alternative therapy for ovarian
cancer”. Selene Nunez-Cruz, Hongchang Qu, Stavros Rafail, Denise Connolly, Phyllis Gimotty, John Lambris,
George Coukos, and Nathalie Scholler. - AACR 2010 Poster presentation. April 19, Washington, DC.
“In vivo blocking of CA125/mesothelin-dependent cell adhesion prevents ovarian cancer peritoneal metastasis”.
Denarda Dangaj, Amber Roberts, Raphael Sandaltzopoulos and Nathalie Scholler. Poster presentation.Society of
Gynecologic Oncologists (SGO) 41st Annual Meeting on Women's Cancer. March 14-17, San Francisco, CA.
“MTB Hsp70-scFv Fusion and Self Assembling Proteins Targeting Mesothelin Control Tumor Growth and
Augment Tumor Specific T Cell Responses In A Murine Model of Ovarian Cancer” Jianping Yuan, Pierre
Leblanc, Elda Righi, Svetlana Korochkina, Jacalyn Rosenblatt, Brett Gotzbecker, Dimitris Tzachanis, Michael
Santosuosso, Sandra Orsulic, Heidi Mills, Nathalie Scholler, David Avigan, Jeff Gelfand and Mark C. Poznansky.
Poster presentation. Symposium Dana Farber/ Harvard Cancer Center ovca/ breast ca meeting. March 5, 2010,
Boston, MA.
“Ovarian tumor infiltrating lymphocytes B (TIL-B) are capable of synthesis and secretion of both pro- and antiangiogenic factors.” Selene Nunez-Cruz, Matthew Guerra, Denise Connolly, George Coukos, Phyllis Gimotty and
Nathalie Scholler - Poster presentation, 13th Annual Meeting of the Translational Research Cancer Centers
Consortium conference, The Ohio State University - March 1-2- Colombus, OH- First Price poster winner.
“The binding of mannose receptor by tumor-released GPI-anchor proteins controls tumor-associated macrophage
phenotype” Authors: Denarda Dangaj, Selene Nunez-Cruz, Aizhi Zhao, Raphael Sandaltzopoulos and Nathalie
Scholler. Poster presentation. 13th Annual Meeting of the Translational Research Cancer Centers Consortium
conference, The Ohio State University - March 1-2- Colombus, OH.
“Development of a screening strategy to identify affinity reagents against formalin-fixed antigen”. Natalia DiazRodriguez, Aizhi Zhao, Nathalie Scholler. Poster presentation. Short-term Elective Research (STER) Summer
Student Symposium – September 11 – University of Pennsylvania, Philadelphia, PA.
“Dual Specificity Suicide Gene Therapy Using Targeted Nanoparticles Directed against Ovarian Cancer”.
Andrew M. Prantner, Patricia Ohana, Abraham Hochberg, Jerry D. Glickson, George Coukos and Nathalie
Scholler. Poster presentation. Biomedical Post Doctoral Research Symposium 2009. University of Pennsylvania,
Philadelphia, PA.
“Tumor infiltrating-B cells (TIL-B) exhibit a regulatory phenotype in a transgenic mouse model of serous ovarian
cancer”. Selene Nunez-Cruz, Matthew Guerra, Denise Connolly, George Coukos, Phyllis Gimotty and Nathalie
Scholler. Poster presentation. Biomedical Post Doctoral Research Symposium 2009. University of Pennsylvania,
Philadelphia, PA.
“Development and validation of a ScFv specific for human glypican-3”. Yonghai Li, Aizhi Zhao, Hong Li,
Oluwasayo Adeyemo, Nathalie Scholler, David Kaplan. Poster presentation. Department of Medicine Research
Page 7
2009
2009
2009
2009
2009
2009
2009
2009
2009
2008
2008
2008
2008
2008
2008
Day - June 5 - University of Pennsylvania, Philadelphia, PA.
“Construction of a large scFv yeast display library and isolation of TEM1-specific antibodies of high affinity for
targeted-imaging and therapy of cancer” Zhao ., Li C., Nunez-Cruz S., Prantner A.M., Coukos G., Siegel D.L.
and Scholler N. Poster presentation. CRRWH annual retreat, University of Pennsylvania - Philadelphia, PA.
“Rescue of anti-tumor macrophages using mannose-receptor targeted recombinant antibodies for ovarian cancer
therapeutics” Dangaj D., Sandaltzopoulos R., Zhao A., Coukos G. and Scholler N. Poster presentation. CRRWH
annual retreat, University of Pennsylvania - May 27- Philadelphia, PA.
“Developing a universal method to prepare scFv-modified nanoparticles for ovarian cancer diagnosis and
therapy”. Prantner A.M., Glickson J.D., Coukos G. and Scholler N. Key note presentation. CRRWH annual
retreat, University of Pennsylvania - May 27- Philadelphia, PA.
“Development of an orthotopic mouse model of serous ovarian cancer for in vivo imaging” Nunez-Cruz S.,
Prantner A.M., Zhao A., Roberts A., Secreto A., Connolly D., Danet-Denoyers G., Coukos G. and Scholler N.
Poster presentation. CRRWH annual retreat, University of Pennsylvania - May 27- Philadelphia, PA.
“Genetic Approach to Study Complement Role in Ovarian Cancer”. Nunez-Cruz S., Connolly D., Roberts A.,
Lambris J.D., Coukos G. and Scholler N. The Journal of Immunology, 2009, 182, 88.24; AAI 2009 - Poster or
oral presentations. -May 8-12 - Seattle, WA. Travel Award, Selene Nunez-Cruz.
“Identification of high affinity scFv antibodies against mouse and human tumor endothelial marker 1 (TEM1)
using yeast-display scFv library derived from autoimmune patients”. Zhao, A, Li, C., Coukos C, Siegel D and
Scholler N. The Journal of Immunology, 2010, 184, 101.20; AAI 2009- Poster or oral presentations. May 8-12 Seattle, WA. Travel Award, Aizhi Zhao.
“Genetic Approach to Study Complement Role in Ovarian Cancer”. Nunez-Cruz S., Connolly D., Roberts A.,
Lambris J.D., Coukos G. and Scholler N. Poster presentation. 12th Annual Meeting of the Translational Research
Cancer Centers Consortium conference, University of Pennsylvania- March 6-7- Philadelphia, PA Third Price
poster winner.
“Blocking the chemical crosstalk between tumor cells and macrophages with recombinant antibodies to trigger
tumor immune rejection.” Dangaj D, Sandaltzopoulos R, Coukos G and Scholler N. Poster presentation. 12th
Annual Meeting of Translational Research Cancer Centers Consortium conference, University of PennsylvaniaMarch 6-7- Philadelphia, PA
“Development of a universal method for targeting nanoparticles with functionally intact scFv”. Prantner A.M.,
Glickson J.D., Coukos G and Scholler N. 12th Annual Meeting of the Translational Research Cancer Center s
Consortium conference, Poster presentation University of Pennsylvania- March 6-7- Philadelphia, PA
“In vivo Modeling and Detection of the Ovarian Cancer Vascular Marker TEM1”. Li C., Swails JC, Hasegawa K,
O'Brien-Jenkins A, Liu Y, El-Deiry WS, Scholler N, Divgi C, Gimotty PA, Grasso L, Coukos G –Third
International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Poster and oral
presentations. AACR - September 22, 2008- Philadelphia, PA. Award winner.
“Novel Tumor Vascular Markers: Useful Biomarkers and Therapeutic Targets in Epithelial Ovarian Cancer”.
Sasaroli D., Kougioumtzidou E., Hammond R., Buckanovich R.J., Sandaltzopoulos R., Scholler N., Gimotty P.A.
and Coukos G. Poster presentation Second International Conference on Ovarian Cancer: State of the Art and
Future Directions - June 26-July 1, 2008 - Rhodes, Greece
“The Influence of Ovarian Cancer Risk-Status on the Diagnostic Performance of the Biomarkers Mesothelin, HE4
and CA125.” Shah C., Lowe K., Paley P., Wallace E., Anderson G., McIntosh M., Andersen R., Scholler N.,
Bergan L., Thorpe J., Urban N., Drescher C. Poster presentation Joint Meeting of the Western Association of
Gynecologic Oncologists (WAGO) and the Felix Rutledge Society (FRS) - June 11-14, 2008 - Fairmont Sonoma
Mission Inn, Sonoma, CA.
“HE4 Bead-Based ELISA: Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies).”
Forrest R., Scholler N., Lowe K., Bergan L., Kampani A., Thorpe J., Gross J., Garvik B. and Urban N. - Poster
presentation. Canary Foundation Early Detection Symposium, May 21-22, Stanford, CA.
“Use of cancer-specific in vivo-biotinylated recombinant antibodies (Biobodies) for serum biomarker discovery.”
Scholler N., Gross J.A., Garvik B., Wells L., Liu Y., Loch C.M., Ramirez A.B., McIntosh M.W., Lampe P.D. and
Urban N. Poster presentation. Canary Foundation Early Detection Symposium, May 21-22, Stanford, CA.
“Vascular Proteins Predict Clinical Outcome in Ovarian Cancer.” Sasaroli D., Gimotty P.A., Hammond R.,
Seedial T., Buckanovich R.J., Katsaros D., Scholler N. and Coukos G. Poster presentation. Canary Foundation
Early Detection Symposium, May 21-22, Stanford, CA
Page 8
2005
“Use of a yeast library of human antibody recognition sequences to develop diagnostic reagents.” Scholler N,
Garvik B and Urban N. Poster presentation. XXII International Conference on Yeast Genetics and Molecular
Biology, Bratislava, Slovakia.
Peer-reviewed research articles (*corresponding author)
1.
Buonavista, N., Balzano, C., Pontarotti, P., Le Paslier, D. and Goldstein, P. 1992. Molecular linkage of human
CTLA-4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics. Jul; 13(3):856-861.
2.
Balzano, C., Buonavista, N., Rouvier, E. and Goldstein, P. 1992. CTLA-4 CD28, similar protein, neighboring
genes. International Journal of Cancer. Suppl 7, 28-32.
3.
Cornillon, S., Foa, C., Davoust, J., Buonavista, N., Gross, J. D. and Goldstein, P. 1994. Programmed cell death in
Dictyostelium. Journal of Cell Science. Oct; 107(10): 2691-2704.
4.
Couissiner-Paris, P., Bourgeois, A., Dessein, H., Bacellar, O., Rodriguez, V. Jr., Kohlstadt, S., Buonavista, N.,
Pene, J. and Dessein, A. J. 1995. Identification of a major T cell immunogen in the anti-schistosome response of
adult residents in an area endemic of Schistosoma mansoni. European Journal of Immunology. 24 (4): 903-910.
5.
Scholler, N., Fu, N., Yang, Y., Ye, Z. M., Goodman, G. E., Hellström, K. E. and Hellström, I. 1999. Soluble
member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with
ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America.
96(20):11531-11536.
6.
Hellström, I., Ledbetter, J. A., Scholler, N., Yang, Y., Ye, Z. M., Goodman, G. E., Pullman, J., Hayden-Ledbetter,
M. and Hellström, K. E. 2001. CD3-mediated activation of tumor-reactive lymphocytes from patients with
advanced cancer. Proceedings of the National Academy of Sciences of the United States of America. Jun 5;
98(12): 6783-6788.
7.
*Scholler, N., Hayden-Ledbetter, M., Hellström, I., Hellström, K. E. and Ledbetter, J. A. 2001. CD83 is a Sialic
Acid-Binding Immunoglobin-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of
Activated CD8+ T Cells. Journal of Immunology. 166: 3865-3872.
8.
*Scholler, N., Hayden-Ledbetter, M., Dahlin, A., Hellström, I., Hellström, K. E. and Ledbetter, J. A. 2002. CD83
Regulates the Development of Cellular Immunity. Journal of Immunology. 168: 2599-2602.
9.
Disis, M. L.+, Scholler, N.+, Dahlin, A., Pullman, J., Knutson, K. L., Hellström, K. E. and Hellström, I. 2003.
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.
Molecular Cancer Therapy. Oct; 2(10):995-1002.(+these authors equally contributed to the work).
10.
McIntosh, M. W., Drescher, C., Karlan, B., Scholler, N., Urban, N., Hellström, I. and Hellström, K. E. 2004.
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecologic
Oncology. 95(1):9-15.
11.
*Scholler, N., Crawford, M., Sato, A., Drescher, C. W., O’Briant, K. C., Kiviat, N., Anderson, G. L. and Urban,
N. Bead-based ELISA assays for validation of ovarian cancer early detection markers. Clinical Cancer Research.
2006. 12: 2117-2124.
12.
*Scholler, N., Garvik, B., Quarles, T., Jiang, S. and Urban, N. 2006. Method for generation of in vivo biotinylated
recombinant antibodies by yeast mating. Journal of Immunological Methods. Dec 20; 317(1-2):132-143. Epub
2006 Oct 30.
13.
*Scholler, N., Garvik, B., Hayden-Ledbetter, M., Kline, T. and Urban, N. 2007. Development of a CA125Mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Letters. Mar 8; 247(1):130136. Epub 2006 May 4.
14.
Bergan, L., Gross, J. A., Nevin, B., Urban, N., and *Scholler, N. 2007. Development and in vitro validation of
anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Letters. Oct 8;
255(2):263-74. Epub 2007 Jun 7.
15.
Loch, C. M., Ramirez, A. B., Liu, Y., Sather, C. L., Delrow, J.J., Garvik, B., Scholler, N., Urban, N., McIntosh,
M. W. and Lampe, P. D. Use of High Density Antibody Arrays to Validate and Discover Cancer Serum
Biomarkers. Molecular Oncology. Volume 1, Issue 3, December 2007, Pages 313-320
16.
*Scholler, N., Lowe, K. A., Bergan, L. A., Kampani, A. V., Ng, V., Forrest, R. M., Thorpe, J. D., Gross, J. A.,
Garvik, B. M., Drapkin, R., Anderson, G. L. and Urban, N. Use of yeast-secreted in vivo biotinylated recombinant
antibodies (biobodies) in bead–based ELISA. Clinical Cancer Research. 2008 May 1:14(9):2647-55
17.
Faca, V., Song, K., Wang, H., Zhang, Q., Krasnoselsky, A., Ireton, R., Newcomb, L., Plentz, R., Glukhova, V.,
Phanstiel, D., Gurumurthy, S., Redston, M. S., Brenner, D., Anderson, M., Misek, D., Scholler, N., Urban, N.,
Barnett, M., Edelstein, C., Goodman, G., Thornquist, M., McIntosh, M., DePinho, R. A., Bardeesy, N. and
Page 9
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Hanash S. Markers for human pancreatic cancer based on plasma proteome analysis of a mouse model. PLoS
Med. 2008 Jun 10;5(6):e123.
Palmer C., Duan X., Hawley S., Scholler N., Thorpe J., Sahota R., Wong M., Wray A., Drescher C., McIntosh M.,
Brown P., Nelson B., Urban N. Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian
Cancer. PLoS ONE - 2008 Jul 9;3(7):e2633.
Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N. Combining a
symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008 Jun 25. Jun 25;113(3):484489. DOI: 10.1002/cncr.23577
*Scholler N., Gross JA., Garvik B., Wells L., Liu Y., Loch CM., Ramirez AB., McIntosh MW., Lampe PD.,
Urban N. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker
discovery. Journal of Translational Medicine. 2008, 6:41
Lowe K., Shah C., Wallace E., Anderson G., Paley P., McIntosh M., Andersen R., Scholler N., Bergan L., Thorpe
J., Urban N., Drescher C. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in
Healthy Post-menopausal Women at High-Risk for Ovarian Cancer. Cancer Epidemiology, Biomarkers &
Prevention. 2008 Sep;17(9):2480-7.
C. Shah, K. Lowe, P. Paley, E. Wallace, G. Anderson, M. McIntosh, R. Andersen, N. Scholler, L. Bergan, J.
Thorpe, N. Urban, C. Drescher. “Influence of ovarian cancer Risk status on the Diagnostic Performance of the
serum Biomarkers Mesothelin. HE4 and CA125”.-Cancer Epidemiology Biomarkers & Prevention (CEBC) Prev.
2009 May;18(5):1365-72
Gonzalez, J.M., Ofori E., Burd I., Chai J., Scholler N., Elovitz M.A.: “Maternal mortality from systemic illness:
unraveling the contribution of the immune response”. Am J Obstet Gynecol 2009, 200, 430 e1-8.
Chen, A., Kozak, D., Battersby, B.J., Forrest, R.M., Scholler, N., Urban, N., and Trau, M. “Antifouling Surface
Layers for Improved Signal-to-Noise of Particle-Based Immunoassays” –Langmuir. 2009, 25 (23), pp 13510–
13515
Anderson G.L., McIntosh M.,Wu L., Thorpe J.D., Bergan L., Goodman G., Barnett M., Thornquist M.D.,
Scholler N., Kim N., O’Briant K., Drescher C., Urban N.. “Assessing Lead Time of Selected Ovarian Cancer
Biomarkers: A Nested Case-Control Study” –JNCI. 2010 Vol. 102, Issue 1, January 6.
Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P and Urban N. “Use of a
Symptom Index, CA125, and HE4 to predict ovarian cancer.” -Gynecol Oncol. 2010 Mar;116(3):378-83. Epub
2009 Nov 28.
Aizhi Zhao, Selene Nunez-Cruz, Chunsheng Li, George Coukos, Don L. Siegel and *Nathalie Scholler. “Rapid
isolation of high affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired
yeast display/secretory scFv library platform.” JIM, Jan 5; 363(2):221-32. Epub 2010 Sep 15.
Selene Nunez-Cruz, Denise C. Connolly and Nathalie Scholler. “An orthotopic model of serous ovarian cancer in
immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.” JoVE , 2010
Nov 28. (45), pii:2146, doi:10.3791/2146. [Epub ahead of print]
Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE,
Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET,
Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project
Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian
cancer. Cancer Prev Res (Phila). 2011 Mar;4(3):375-83.
Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW,
Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang
Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer
screening trial specimens. Cancer Prev Res (Phila). 2011 Mar;4(3):365-74.
Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K,
Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G. Novel surface targets and serum biomarkers from the
ovarian cancer vasculature. Cancer Biol Ther. 2011 Aug 1;12(3). [Epub ahead of print] PubMed PMID:
21617380
Nicole Urban, Jason D. Thorpe, Martin McIntosh, Lindsay Bergan, Robin Forrest, Archana Kampani, Nathalie
Scholler, Kathy O’Briant, Charles Drescher, Dan Cramer, Chris Berg. "Potential role of HE4 in multimodal
screening for epithelial ovarian cancer" JNCI brief communication 2011; 103:1-5 [Epub ahead of print.]
Evripidis Lanitis, Mathilde Poussin, Ian Hagemann, Raphael Sandaltzopoulos, Nathalie Scholler, and Daniel J.
Powell, Jr. “Redirected anti-tumor activity of primary human lymphocytes transduced with a fully-human antimesothelin chimeric receptor”. Molecular Therapy (in press)
Page 10
34.
Denarda Dangaj, Karen Abbott, Ananda Mookerjee, Aizhi Zhao, Pamela S. Kirby, Raphael Sandaltzopoulos,
Daniel J. Powell Jr., Antonin Lamazière, Don L. Siegel, Claude Wolf, and *Nathalie Scholler. “Mannose receptor
engagement by mesothelin GPI anchor polarizes tumor associated macrophages and is blocked by a recombinant
antibody directed against mannose receptor domain 4.” PLos One (In press).
Submitted peer-reviewed research articles.
Eleftheria Kalogera; Nathalie Scholler; Cecelia Powless; Amy Weaver; Ronny Drapkin; Jinping Li; Shi-Wen Jiang; Karl
Podratz; Nicole Urban; Sean Christopher Dowdy. “Correlation of Serum HE4 with Tumor Size and Myometrial
Invasion in Endometrial Cancer”. Accepted pending minor revisions. Gynecologic Oncology
Reviews
*Scholler, N. and Urban N. CA125 in Ovarian Cancer. Biomarkers in Medicine 1(4), December 2007, Pages 513-523.
*Scholler, N., Mesothelin, Encyclopedia of Cancer, 2nd edition, 1836-1940 (2008)
*Scholler, N.,2nd Oncology Biomarkers Conference (Miami, FL), Thomson Reuters Scientific division (2009)
*Scholler, N.6th Cancer Drugs R&D Conference (Philadelphia, PA), , Thomson Reuters Scientific division (2009)
*Scholler N., “Oncology Biomarkers. the Investigational Drugs journal 2009 12(4): © Thomson Reuters (Scientific) Ltd
ISSN 2040-3410
Sasaroli D., Coukos G. and *Scholler N. “Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there
yet?” - Biomarkers in Medicine. Prev. 2009 May;18(5):1365-72
Tanyi J.L and *Scholler N. “From the endometrium physiology to a comprehensive strategy for the discovery of ovarian
cancer biomarkers.” Oncology reviews. 2010 March, Vol. 4, Number 1, pages 43-50.
*Scholler, N, 3rd Oncology Biomarkers Conference (San Diego, CA), Thomson Reuters Scientific division. (2011)
Tanyi, J.L. and *Scholler, N. “Oncology Biomarkers for Detection and Therapeutic Monitoring of Gynecologic
Malignancies”. Frontiers in Biosciences. (in press)
Book Chapters
*Scholler, N. "Selection of antibody fragments by yeast display" chapter of “Antibody Engineering: methods and
protocols" section in the lab-protocol based 'Methods in Molecular Biology' series, Humana Press editors. (in
press)
Mantia-Smaldone, G.M. and *Scholler, N. "Ovarian Cancer" chapter of InTech book project, Open Access publisher.
ISBN: 978-953-307-812-0. (in press)
Editorial
*Scholler, N. Novel targeting strategies using recombinant antibodies for early diagnosis and therapy of ovarian cancer.
Future Medicine Therapy. 2010, 7(3), 209-212
Patents
1.
2.
3.
4.
Scholler N. and Garvik B., US Patent No. 7,795,411 (“Methods of Generation of in vivo biotinylated recombinant
antibodies”).
Law CL, Pestano LA, Wahl AF, and Scholler N, US Patent No. 7,662,387 (“Anti-CD70 antibody-drug conjugates
and their use for the treatment of cancer and immune disorders”).
Law CL, Pestano LA, Wahl AF, and Scholler N, US Patent Application No. 12/467,182 (“Anti-CD70 antibodydrug conjugates and their use for the treatment of cancer and immune disorders”).
Law CL, Pestano LA, Wahl AF, and Scholler N, US Patent Application No. 12/635,571 (“Treatment of B-cell
cancers with anti-CD70 antibody drug conjugates”).
Page 11
5.
6.
7.
8.
9.
10.
11.
12.
13.
Law CL, Pestano LA, Wahl AF, and Scholler N, US Patent Application No. 12/635,607 (“Treatment of renal cell
carcinoma with anti-CD70 antibody-drug conjugates”).
Scholler N, Disis ML, Hellström I, and Hellström KE, US Patent No. 6,734,172 (“Surface receptor antigen
vaccines”).
Ledbetter JA, Scholler N, Hayden-Ledbetter M, Hellström I, and Hellström KE, US Patent Application No.
10/098,221 (“Compositions and methods to regulate an immune response using CD83 gene expressed in tumors
and using soluble CD83-Ig fusion protein”).
Ledbetter JA, Scholler N, Hayden-Ledbetter M, Hellström I, and Hellström KE, US Patent Application No.
11/600,927 (“Compositions and methods to regulate an immune response using CD83 gene expressed in tumors
and using soluble CD83-Ig fusion protein”).
Scholler N, Hellström I, and Hellström KE, US Patent No. 6,770,445 (“Methods and compositions for diagnosing
carcinomas”).
Scholler N, Hellström I, and Hellström KE, US Patent No. 7,745,159 (“Methods and compositions for diagnosing
carcinomas”).
Scholler N, Hellström I, and Hellström KE, US Patent Application No. 12/781,231 (“Methods and compositions
for diagnosing carcinomas”).
Scholler N, Zhao, Siegel DL, and Coukos G, International Patent Application No. PCT/US10/56477 (“AntiTEM1 antibodies and uses thereof”)
Powell DJ and Scholler N, A fully human, anti-mesothelin specific chimeric immune receptor for redirected
mesothelin-expressing cell targeting. US provisional patent application No. 81/552,820, filed on October 28, 2011
Page 12
Mentoring and teaching activities
Received Training
2008
The Art of Speaking: Professional Communication for Faculty
2008
Effective Abstract Writing
2008
The Art of Award Winning Poster Presentations
2010
Overview of Education at Penn Medicine Workshop
2010
Writing Letters of Recommendation for Trainees
2010
Interactive Teaching
2011
Effective Lecturing
Administrative Teaching Activities
Dates
Position/title
Since 2008
IGG Recruitment
committee member
Judge and mentor
Since 2010
06/02/2010
04/06/2011
05/19/2011
07/18/2011
Fall 2011
Organization
Biomedical Graduate Group (IGG)
Annual AACR Undergraduate Student
Caucus and Poster Competition.
Facilitator
Responsible Conduct in Research (RCR)
workshop
Mentor
AACR, Special Program for High School
Students
Committee member Biomedical Graduate Group, Cancer
for Rafael Winograd Biology. Thesis Preliminary exam.
Committee member Bioengineering Graduate Group,
for Ajlan Al Zaki
Cellular and Molecular Imaging.
Thesis Preliminary exam.
Moderator
Monday Night Journal Club, Immunology
Location
Frequency
Annual
Total
hrs/yr
4
Annual
8
Perelman School of
Medicine
AACR meetings
Once
2
Once
2
Perelman School of
Medicine
Penn School of
Bioengineering
Once
4
Once
4
Perelman School of
Medicine
Annual
3
Perelman School of
Medicine
AACR meetings
Teaching
Date
Teaching type
2007
Workshop
Recombinant antibodies
2008
Lecture
Yeast-display scFv
2009
Lecture
2009
Directed reading
(Imm 520)
Lecture
(CBE 564)
Introduction to innate
and adaptive immune
systems & inflammation
Role of B cells in solid
tumor
Targeted therapies
2010
Since 2010 Lecture
(Imm 599)
2010
Lab rotation
(Imm 699)
Since 2010 Course
(CAMB 701)
2011
Course
(Imm 508)
Title
Immunology Faculty
Research Seminar
Yeast-display scFv
screening
Tumor
microenvironment
Humoral responses
in cancer
Location
Type and number Frequency Total
of students
hrs/yr
Fred Hutchinson CRC, 30 Post-doctoral
Once
2
Seattle, WA
fellows
Cold Spring Harbor, NJ 40 Post-doctoral
Once
2
fellows
Biostatistic Graduate
7 graduate students Once
2
Group, Upenn.
Biomedical Graduate
Group, Upenn.
Bioengineering
Graduate Group,
Upenn,
Biomedical Graduate
Group, Upenn.
Perelman School of
Medicine.
Biomedical Graduate
Group, Upenn.
Biomedical Graduate
Group, Upenn.
Page 13
1 graduate students
Natalie Steinel
21 undergraduate
students
Once
10
Once
1
~15 graduate
students
1 graduate student
Nicole Martinez
9 graduate students
Annual
0.5
Once
12
Annual
30
4 graduate students
Once
36
2011
Lab rotation
(CAMB 699)
Mannose receptor
polymorphism
Biomedical Graduate
Group, Upenn.
1 graduate student
Once
Michael Allegrezza
12
Trainees
Graduate students
Date
Position in my lab
2008-present PhD Student/
visitor scientist
(PENN lab)
Name
Denarda Dangaj
Publications, abstracts and awards
Publication:
PlosOne 1st author
Abstracts & Awards:
SITC 2011;
AAI 2011, JI supplement;
Best presentation CRRWH 2010
Post-doctoral fellows
2005-2006 Post-doctoral Fellow Sanjiban Barnejee
(FHCRC lab)
2008-2009
2008-2010
Post-doctoral Fellow Selene Nunez(PENN lab)
Cruz
Post-doctoral Fellow Aizhi Zhao
(PENN lab)
2008-present Post-doctoral Fellow Andrew Prantner
(PENN lab)
2010-2011
Current position
PhD Student/visitor
scientist in my lab
Founder of AbGenics,
National Chemical
Laboratory, Pune, India
Publications:
JIM 2010, 2nd author.
JoVE 2010, 1st author.
J Exp Med in prep, 1st author.
Abstracts & Awards:
AAI 2009, Travel Award, JI suppl.
AAI 2010, Trainee Achievement
award, JI suppl.
AAI 2011, Travel Award, JI suppl.
Third price poster presentation
TRC3 2009
First price poster presentation TRC3
2010
Publications:
JIM 2010, 1st author.
PLos ONE 2011, 4th author.
J Exp Med in prep., 4th author.
Abstracts & Awards:
AAI 2009, Travel Award, JI suppl.
Abstracts & Awards:
Keynote speaker, CRRWH
Post-doctoral Fellow Ananda Mookerjee Publication: PLos ONE 3rd author
(PENN lab)
Research associate in
my lab since April
2010.
Research
associate
since November 2010
(Coukos lab, OCRC).
Post-doctoral Fellow in
my lab.
Post-doctoral
Fellow
(Coukos lab, OCRC)
Mentoring
2011
2010-11
2010-11
2010-11
2010-11
2010-11
2010
Summer Internship
Elizabeth Blackwell Society
Senior Design Project
Senior Design Project
Senior Design Project
Senior Design Project
Summer Internship
Norma A. Brown
Katie Manning
Andrew Lee
Kevin Chu
Matt Cha
Xiao Ling
Ashley Jordan
2009-10
Elizabeth Blackwell Society Charlotte Lawson
Page 14
Undergrad. in Bioengineering, Penn School of Engineering
First year Medical school student, Penn School of Medicine
Undergrad. in Bioengineering, Penn School of Engineering
Undergrad. in Bioengineering, Penn School of Engineering
Undergrad. in Bioengineering, Penn School of Engineering
Undergrad. in Bioengineering, Penn School of Engineering
Undergraduate in Biochemistry, Special Programs
Biomedical Graduate Studies, UPenn, PA.
First year Medical school student, Penn School of Medicine
2009-10
Senior Design Project
Kolin Hribar
2009-10
Senior Design Project
Gregory Wiedman
2009
2009
Independent work study
Independent work study
2008
Visitor scientist
Tamara Seedial
Natalia
Diaz-Rodriguez
Murielle Saade
Page 15
Undergrad. in Bioengineering, Penn School of Engineering.
Now a graduate student at UC, San Diego, CA.
Undergrad. in Bioengineering, Penn School of Engineering.
Now a graduate student at John Hopkins, Baltimore, MA.
Masters in Biotechnology, Penn School of Engineering.
NIH-funded Short Term Training, PhD student, University
of Pennsylvania.
Graduate student, University of Aix- Marseille II, France
Now a post-doctoral fellow in Barcelona, Spain.
AUGMENTED CURRICULUM VITAE
Funded Research
ACTIVE
1R01CA156695-01
Coukos (PI), Scholler (Co-Inv)
09/1/10-08/31/15
1.2 calendar
Transformative personalized vascular disrupting cancer immunotherapy.
$484,107
To solve current limitations in the field of cancer vascular therapy and generate personalized approach of autologous
adoptive vascular disrupting lymphocyte immunotherapy applicable to most tumor types. T cells will be engineered with
lentiviral vectors to express chimeric immunoreceptors (CIRs), fusion molecules comprising an extracellular single chain
variable fragment (scFv) antibody domain and intracytoplasmic CD3, CD28 and 4-1BB signaling domains for robust Tcell activation. Patient-derived lymphocytes will be genetically reprogrammed to recognize, get activated by and destroy
specifically the tumor vasculature.
P01 AI 068730 (Lambris; Project #2) Coukos (PI), Scholler (Co-Inv)
09/01/07 – 08/30/12 2.88 calendar
NIH/NCI
$142,593
Complement in Cell Proliferation and Injury-Therapeutic Interventions.
The two mails goals of the project are to determine the role of complement in tumor progression in ovarian cancer and of
C3a and C5a anaphylatoxins in promoting angiogenesis and altering antitumor immune response.
1R21CA152540-01A1
Powell (PI), Scholler (Co-PI)
12/01/10-11/30/12 1.8 calendar
Tailored antigen specificity for personalized adoptive T cell therapy of cancer
$125,000 annual directs/year
To engineer a transduced docking system for T cells permitting the loading and self assembly of biobodies on T cells to
generate T bodies for high-throughput screening.
W81XWH-09-BCRP-IDEA
Coukos (Initiating PI), Scholler (Partner PI)
05/15/10 - 04/31/12 1.8 calendar
DOD (IDEA Breast cancer award)
$198,113
Targeting Breast Cancer with T cells Redirected to the Vasculature.
To engineer targeted T cells (T body) with anti-tumor vasculature marker recombinant antibodies (scFv) against tumor
vasculature markers, including TEM1, to kill breast cancer cells.
N/A
Scholler (PI)
11/15/10-11/14/11 0.12 calendar
PENN Nanotoxicology Alliance
$25,000
Synthesis, characterization and toxicity studies of biocompatible phospholipid-coated iron oxide nanoparticles containing
cobalt for thermal cancer therapy
This pilot project proposes to synthesize superparamagnetic nanoparticles with improved biocompatibility through PEG
coating, and increased effectiveness of magnetic field hyperthermia through cobalt incorporation. In vitro biocompatibility
and toxicity of the nanoparticles will be systematically addressed in vitro.
Career Development Award
Scholler (PI)
11/01/09- 09/30/11 0.24 calendar
NIH/NCI FCCC/UPenn SPORE in Ovarian cancer (Seiden/Coukos)
$75,000/year
Study of a novel mechanism of tumor tolerization mediated by the binding to mannose receptor of tumor-released GPIanchor glycoproteins.
To analyze specific glycomics and lipidomic structures of tumor-released PI-anchors, assess in vivo the role of mannosereceptor in tumorogenesis in mannose-receptor knockout mice and to identify small molecules able to block GPI
anchor/mannose receptor interactions for therapeutic purposes.
Private funding
Danet-Desnoyers (PI), Scholler (Co-PI)
Centocor, Inc.
Modeling the human tumor microenvironment in mice.
PENDING
1R01CA164085-01 (Scholler)
09/01/2011 - 08/31/2016
NIH/NCI
Targeting of biocompatible paramagnetic nanoparticles for cancer thermoablation
Page 16
07/01/11-06/30/12 2.28 calendar
Annual directs Scholler: $112,396
3 calendar
$250,000
R21
Scholler (PI)
02/01/12-01/30/14
NIH – scored in 20% percentile. JIT
$150,000/year
“Linking tumor chemoresistance to TLR variants that mediate damage chain reaction.”
3.6 calendar
OC110673 (Scholler)
09/01/2012 - 08/31/2014
1.2 calendar
DOD
$131,957
A New Paradigm for Simultaneous Immunomodulation of the Tumor Microenvironment and Direct Ovarian Cancer Cell
Eradication Using B7-H4-Based Targeting
BC111175 (Scholler)
09/30/2012 - 09/29/2014
1.8 calendar
DOD
$125,846
Role of the Immunomodulatory Molecule B7-H4 in the Conversion of Ductal Carcinoma in situ (DCIS) to Invasive
Cancer
OVERLAP: If funding of a new award causes actual committed effort to exceed 100%, a resolution will be negotiated
with the funding agencies involved.
COMPLETED
Pilot project
Scholler (PI)
06/01/10-05/31/11 0.72 calendar
Penn Institute For Immunology, University of Pennsylvania
"Role and identification of molecular variants of complement factor H (CFH) and complement factor B (BF)/complement
component 2 (C2) in ovarian cancer".
To screen ovarian cancer tissues and sera for factor H variants, and to assess the role of factor H and factor B in a
transgenic mouse model of ovarian cancer.
Private funding
Danet-Desnoyers (PI), Scholler (Co-PI)
04/01/10-03/31/11 2.28 calendar
Centocor, Inc.
“Modeling the human tumor microenvironment in mice.”
To model and optimize the reconstitution of human immune system in profoundly immuno-suppressed mice using CD34
cells from human bone marrow.
Private funding
Scholler (PI)
12/01/07 – 11/30/10 0.24 calendar
Claneil Foundation
“Development of novel ovarian cancer early detection tools using novel molecular carriers called nanoparticles carrying
contrast agents directed against the tumor vasculature.”
Improving the outcomes of ovarian cancer by facilitating earlier detection is urgently needed. We proposed to develop
new blood tests, new imaging tools and other innovative techniques to detect ovarian cancer early.
TAPITMAT
Scholler (PI)
07/01/09-09/30/10
CA016520/NIH Institute for Translational Medicine and Therapeutics (ITMAT)
“TEM1-Based Cancer Detection and Therapy.”
Tumor endothelium marker-1 (TEM1) is specifically expressed in tumor vasculature and is absent in normal blood vessels
and other adult tissues. We proposed to develop perfluorocarbon (PFC) based immuno-nanoparticles for detection and
intravascular radio-immunotherapy of TEM1-expressing TV cells for ovarian cancer.
Private funding
Scholler (PI)
08/01/09-06/31/10
Institute for Systems Biology
“Technology development for assessment of glycosylation changes using surface plasmon resonance and mass
spectrometry”.
Improving early diagnostic of ovarian cancer by detection of glycosylation changes would transform patient prognosis.
We proposed to develop recombinant antibodies (biobodies) against 4 glycopeptides for SISCAPA applications at ISB.
Developmental Research Project
11/01/07 – 03/31/09
Scholler (PI)
Page 17
P50 CA 83636 (Urban) NIH/NCI Pacific Ovarian Cancer Research Consortium: SPORE in Ovarian Cancer.
“Blocking of CA125/mesothelin-dependant metastasis with antibodies and biobodies”.
The goal of this grant was to develop a novel CA125-positive luciferase-expressing ovarian cancer xenograft in
NOD/SCID mice, to correlate peritoneal metastatic burden with CA125 titers, and to evaluate the therapeutic value of
anti-CA125 and anti-mesothelin mAb and biobodies.
Pilot project
Scholler (PI)
01/01/08-12/31/08
ACS IRG - Abramson Cancer Center of the University of Pennsylvania
“Role of mannose receptor in macrophage polarization toward a tumor-associated phenotype.”
The goal of this grant was to assess in vitro the role of mannose-receptor in tumorogenesis and in macrophage phenotype
switch, and to develop affinity reagents (scFv) able to detect and functionally block mannose receptor.
Pilot Project
Scholler (PI)
06/01/05 - 05/31/07
Private Funding from Entertainment Industry Foundation (Hartwell)
“Improving Early Detection of Breast Cancer with a Blood Test”
This pilot project aimed to generate scFv subtractive libraries specific for peptides or proteins differentially expressed in
breast cancer patient samples to compare with control samples.
Developmental Research Project
Scholler (PI)
08/01/06 - 07/30/07
P50 CA 83636 (Urban) NIH/NCI Pacific Ovarian Cancer Research Consortium: SPORE in Ovarian Cancer
“Study of the role of CA125 and adipocytes in the alternative complement pathway during ovarian cancer
physiopathology.”
This developmental research project aimed to better understand the role of CA-125 and adipocytes in the Alternative
Complement Pathway.
Developmental Research Project
Scholler (PI)
07/01/05 - 06/30/06
P50 CA 83636 (Urban) NIH/NCI
“Blocking of the CA125-mesothelin interaction with diabodies to prevent the implantations of ovarian carcinoma
metastasis.”
This developmental research project aimed to develop therapeutic agents that have the potential for treating metastatic
disease in mesothelin-dependant cancers.
Pilot project
Scholler (PI)
07/01/04 – 06/30/05
Fred Hutchison Cancer Research Center, Seattle, WA.
“Development of a model system to study the role of processing in the CA125-mesothelin interaction.”
The aim of this study was to determine whether proteolytic processing of nascent mesothelin is necessary to produce a
mature form that is competent to bind to CA125 and to thereby initiate the process of tumor cell adhesion and invasion.
Scholar Award.
Scholler (PI)
09/30/01 – 10/01/03
Marsha Rivkin Center for Ovarian Cancer Research, Seattle, WA
This award provided an opportunity for Dr. Scholler to work with senior scientist mentors (Nora Disis, MD, from the
University of Washington, and Jeffery Ledbetter, PhD, from Pacific Northwest Research Institute). Dr. Scholler’s specific
research interests were investigating the immune response to ovarian cancer and developing ovarian cancer vaccines.
Page 18